OCUSERT PILO-40
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUSERT PILO-40 (OCUSERT PILO-40).
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
| Metabolism | Primarily metabolized by plasma esterases via hydrolysis, with minor hepatic metabolism (CYP450 not significantly involved). |
| Excretion | Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system. |
| Protein binding | Binding to plasma proteins is negligible (<10%); primarily bound to tissue proteins in the eye. |
| Volume of Distribution | 0.3-0.6 L/kg in systemic circulation; local ocular distribution is extensive but systemic Vd is low. |
| Bioavailability | Systemic bioavailability is minimal (<1%) due to local ocular administration and first-pass hydrolysis; virtually 100% of the released dose is available locally in the eye. |
| Onset of Action | Ocular (insertion): 1-2 hours; peak intraocular pressure reduction occurs at 4-6 hours. |
| Duration of Action | Up to 7 days with Ocusert Pilo-40 (40 µg/h release rate); therapeutic effect (miosis and IOP reduction) maintained for one week after single insertion. |
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
| Dosage form | INSERT, EXTENDED RELEASE |
| Renal impairment | No specific adjustment required; pilocarpine is primarily metabolized in the eye and systemic absorption minimal. GFR not relevant. |
| Liver impairment | No specific adjustment required; pilocarpine undergoes minimal hepatic metabolism. Child-Pugh not applicable. |
| Pediatric use | Not established; safety and efficacy in pediatric patients not determined. Use only if clearly needed. |
| Geriatric use | No specific dose adjustment; consider potential increased risk of systemic effects due to reduced tear production or conjunctival changes. Monitor for bradycardia, hypotension, or bronchospasm. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCUSERT PILO-40 (OCUSERT PILO-40).
| Breastfeeding | Pilocarpine is excreted into breast milk. The M/P ratio is not established. Due to potential for systemic absorption in the infant, use while breastfeeding is not recommended. Monitor infant for cholinergic effects. |
| Teratogenic Risk | Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and third trimesters, use may cause fetal bradycardia and hypotension. The benefit must justify the potential risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to pilocarpine or any component","Patients with acute inflammatory disease of the eye (e.g., iritis, uveitis)","Uncontrolled asthma or severe bradycardia (systemic effects)"]
| Precautions | ["Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia","May cause transient or permanent miosis leading to reduced vision in low light","Ciliary spasm, headache, and brow ache","Potential for systemic absorption causing bradycardia, hypotension, and bronchospasm","Caution in patients with asthma, bradycardia, or hypotension"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal intraocular pressure, heart rate, and blood pressure. Fetal monitoring is recommended, especially in the third trimester, for signs of bradycardia or other cholinergic effects. Ultrasound may be considered to assess fetal growth and wellbeing. |
| Fertility Effects | No specific studies on human fertility. In animal studies, pilocarpine did not show adverse effects on fertility. However, cholinergic agents may theoretically influence ovulation and implantation. Use with caution in women attempting conception. |